Biosimilars
•11 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (11)
| Company | Market Cap | Price |
|---|---|---|
|
ABT
Abbott Laboratories
Abbott's biosimilars pipeline signals growth potential in biosimilar therapeutics, aligning with the Biosimilars investable theme.
|
$220.08B |
$128.22
+1.40%
|
|
AMGN
Amgen Inc.
Amgen maintains a significant Biosimilars portfolio with multiple launches since 2018.
|
$172.66B |
$329.68
+2.79%
|
|
VTRS
Viatris Inc.
Viatis pursues biosimilar opportunities alongside its generics portfolio.
|
$14.42B |
$12.46
+0.69%
|
|
RDY
Dr. Reddy's Laboratories Limited
Significant emphasis on biosimilar development and commercialization.
|
$11.53B |
$13.87
+0.36%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Amneal is expanding into biosimilars, a core diversification from traditional generics.
|
$3.99B |
$13.02
+2.40%
|
|
HROW
Harrow Health, Inc.
Strategic biosimilars portfolio in ophthalmology (BYOOVIZ, OPUVIZ) with Samsung Bioepis.
|
$2.03B |
$53.72
-1.97%
|
|
OGN
Organon & Co.
Biosimilars portfolio (Hadlima, Renflexis, Ontruzant, Tofidence) represents a major product line.
|
$1.93B |
$8.07
+8.47%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Amphastar is advancing biosimilar programs (AMP-004) and positions biosimilars as a core growth pillar.
|
$1.24B |
$27.58
+3.22%
|
|
KMDA
Kamada Ltd.
Biosimilar product distribution is a key existing business line for Kamada's expanded portfolio.
|
$416.15M |
$7.38
+2.00%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RT-111 and RT-105 include ustekinumab and adalimumab biosimilars, fitting the biosimilars category.
|
$97.74M |
$1.39
+1.84%
|
|
SCNX
Scienture Holdings, Inc.
SCN-106 is described as a potential biosimilar, fitting the Biosimilars investable theme.
|
$8.46M |
$0.53
+1.39%
|
Loading company comparison...
Loading industry trends...
Loading research report...
